AI Summary & Key Takeaways
AI InsightConclusion: Low hemoglobin level predicts clopidogrel resistance independently of other clinical variables
📌 3 Key Takeaways
Abstract
AbstartObjective: Antiplatelet therapy is an indispensable part of current coronary artery disease and resistance to ADP inhibitors leads to adverse cardiovascular events in patients. In this study, it was aimed to detect clopidogrel resistance markers in patients undergoing percutaneous coronary intervention. METHODS: Eighty consecutive patients (38 clopidogrel resistance, 42 controls) who underwent percutan intervention procedure due to coronary artery disease and who had tested positive for clopidogrel resistance at the end of the first week were included in the study. In the VerifyNow test,> 208 platelet reactivity unit clopidogrel resistance and> 550 aspirin reaction unit were accepted as aspirin resistance. 28 patients were treated with ST elevation MI, 18 patients without ST elevation MI, and the other patients were treated for stable coronary disease. Demographic findings, CV and family background variables, body mass index, injection fraction, aspirin resistance and biochemical parameters were compared. Findings: The mean age of the patients was 59 ± 12 and 15 were female. Subjects with clopidogrel resistance were significantly lower in Hemoglobin values. Resistance was more frequent in hypertension, while female sex and smokers were more frequent. Logistic regression analysis showed that hemoglobin (odds ratio = 0.8; 95% safety interval (0.678-0.945), p = 0.008] significantly predicted clopidogrel resistance. Conclusion: Low hemoglobin level predicts clopidogrel resistance independently of other clinical variables